Navigation Links
U.S. Government Grants Awarded for Further Development of Adult Stem Cell Products
Date:11/8/2010

MELBOURNE, Australia, Nov. 8, 2010 /PRNewswire/ -- Regenerative medicine company, Mesoblast Limited (ASX: MSB; USADR: MBLTY), today announced that its United States associate company, Angioblast Systems, has been awarded $1.2 million in grants under the United States Government's Qualifying Therapeutic Discovery Project (QTDP) program.

Angioblast received the maximum grant amount awarded for each of the five projects that were eligible for QTDP funding.  The projects, selected jointly by the United States Treasury Department and the Department of Health and Human Services, relate to the company's adult stem cell products for congestive heart failure, heart attack, oncology, eye and diabetes indications.

"We are pleased to have received this cash award, and will use the funds to advance our objectives for product commercialization," said Mesoblast Chief Executive Professor Silviu Itescu.

The QTDP program was enacted as part of the Patient Protection and Affordable Care Act of 2010 to provide tax credits to eligible companies in order to encourage investments in new therapies for prevention or treatment of acute and chronic diseases.  Companies, such as Angioblast Systems, that cannot currently use a tax credit were allowed to apply for a cash grant in lieu of a tax credit.

To be eligible for the program, projects had to show reasonable potential to result in new therapies to treat areas of unmet medical need, prevent, detect, or treat chronic or acute disease and conditions, or reduce long-term health care costs in the United States.  Preference was given to projects that showed the greatest potential to create and sustain (directly or indirectly) high quality, high-paying jobs in the United States, and advance United States competitiveness in the fields of life, biological, and medical sciences.

"The award serves as further external recognition, in this case by the United States Government, of the strength and promise of our adult stem cell technology platform to deliver effective therapies for a range of conditions currently in great medical need," said Professor Itescu.

About Mesoblast

Mesoblast Limited (ASX: MSB; USADR: MBLTY) is a world leader in commercializing biologic products for the broad field of regenerative medicine. Mesoblast has the worldwide exclusive rights for a series of patents and technologies developed over more than 10 years relating to the identification, extraction, culture and uses of adult Mesenchymal Precursor Cells (MPCs). www.mesoblast.comContact:Julie MeldrumMesoblast Limited+61 3 9639 6036    julie.meldrum@mesoblast.com
'/>"/>

SOURCE Mesoblast Limited
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Lentigen Awarded $1.2 Million by U.S. Government Under the Qualifying Therapeutic Discovery Project
2. Regado Biosciences Awarded Three Grants from the Federal Government to Advance Research of Lead Programs
3. Ardea Biosciences Awarded a $733,438 Grant from the U.S. Government Under the Patient Protection and Affordable Care Act
4. BioSpec Global Solutions Inc hopes to receive confirmation from Chinese government for testing of TOGS™ 9000
5. Curemark Attends North American Bio Forum at Canadian Government Invitation
6. Elusys Awarded Additional $40.6 Million Under Existing U.S. Government Contract to Fund Advanced Development of Anthim, a New Treatment for Anthrax
7. The Irish Government and the Irish Voice Recognize Fibrocell Science, Inc.s Declan Daly as Irish Life Science 50 Member
8. AMA Honors NIH Chief Molecular Biologist Ira Pastan, M.D. With Top Government Service Award
9. U.S. Government Awards DuPont, Partners with Technology Investment Agreement for Macroalgae-to-Biobutanol Research
10. Brazilian Sugarcane Industry Association Stresses Need for Brazils Government to Announce Ethanol Import Tariff Cut as Soon as Possible
11. North Carolina-based Cnanoz Unveils NanoPure(TM) to Government Leaders in Hyderabad, India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... BioMedGPS announces expanded coverage of ... newest module, US Hemostats & Sealants. , SmartTRAK’s US Market for Hemostats and ... synthetic sealants and biologic sealants used in surgical applications. BioMedGPS estimates the market ...
(Date:10/11/2017)... (PRWEB) , ... October 11, 2017 , ... Personal eye wash is a basic first ... eye at a time. So which eye do you rinse first if a dangerous substance ... Plum Duo Eye Wash with its unique dual eye piece. , “Whether its ...
(Date:10/11/2017)... Tbilisi, Georgia (PRWEB) , ... October 11, 2017 , ... ... disaster, taking the lives of over 5.5 million people each year. Especially those living ... the greenovative startup Treepex - based in one of the most pollution-affected countries globally ...
(Date:10/10/2017)... ... October 10, 2017 , ... For the ... won a US2020 STEM Mentoring Award. Representatives of the FirstHand program travelled to ... Experience from US2020. , US2020’s mission is to change the trajectory of STEM ...
Breaking Biology Technology:
(Date:3/29/2017)... 29, 2017  higi, the health IT company that ... North America , today announced a Series B ... of EveryMove. The new investment and acquisition accelerates higi,s ... to transform population health activities through the collection and ... higi collects and secures data today on behalf ...
(Date:3/27/2017)... 27, 2017  Catholic Health Services (CHS) has ... Society (HIMSS) Analytics for achieving Stage 6 on ... . In addition, CHS previously earned a place ... an electronic medical record (EMR). "HIMSS ... of EMR usage in an outpatient setting.  This ...
(Date:3/24/2017)... 24, 2017 Research and Markets has announced ... Analysis & Trends - Industry Forecast to 2025" report to ... The ... a CAGR of around 15.1% over the next decade to reach ... analyzes the market estimates and forecasts for all the given segments ...
Breaking Biology News(10 mins):